Format

Send to

Choose Destination
Hum Vaccin Immunother. 2014;10(11):3313-21. doi: 10.4161/21645515.2014.973314.

To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Author information

1
a Department of Microbiology and Immunology; Hollings Cancer Center ; Medical University of South Carolina ; Charleston , SC USA.

Abstract

T cell adoptive therapies for immune-mediated regression of cancers have attracted a great deal of recent attention. Clinical results are glamorous, yet much remains to be uncovered behind the basic science that allows us to engineer T cells and T cell receptors (TCRs) for clinical use. We discuss the development of TCRs for therapeutic use in the context of thymic selection toward central tolerance and we review therapies based on tumor infiltrating lymphocytes (TILs), endogenous antigen specific TCRs, and engineered TCRs. Further we discuss the development of low and high affinity TCRs and the extent to which each challenges central tolerance. Current results suggest that adaptation of TCR engineering of moderate affinity TCRs coupled with co-regulatory and stimulatory molecules may be the safest and most efficacious road for TCR development aimed at tumor abolition.

KEYWORDS:

AIRE, autoimmune regulator; CDR, complementarity determining region; CTA, cancer testis antigen; MHC, major histocompatibility complex; SLEC, short-lived effector cell; T cell receptor; TAA, tumor-associated antigen; TCR, T cell receptor; TIL, tumor infiltrating lymphocyte; TSA, tissue-specific self-antigen; adoptive cell therapy; affinity; cancer; co-receptor; mTEC, medullary thymic epithelial cell; tumor

PMID:
25483644
PMCID:
PMC4514023
DOI:
10.4161/21645515.2014.973314
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center